Question

Regarding Bromocriptine, which of the following statement is TRUE‐ It is a relatively selective dopamine D2 agonist with prominent action
A. on pituitary lactotrophs (inhibit prolactin release) 
B. in striatum (antiparkinsonian) 
C. in CTZ (antiemetic) ATP γ K 5) 6) 7) 
D. as an adjunctive treatment for type 2 DM 
Choose the correct answer from the options given below:

• A. A, B and D only
• B. A, B and C only
• C. B and D only
• D. A and B only

Answer 1

The Correct Option is A

Bromocriptine is a well-known dopamine agonist, primarily acting as a selective dopamine D2 receptor agonist. Let's analyze each option to determine the true statements:

1. Action on pituitary lactotrophs (inhibit prolactin release): Bromocriptine is used to treat conditions like hyperprolactinemia that involve excessive prolactin production. It acts on pituitary lactotrophs to inhibit the release of prolactin by stimulating D2 receptors. Thus, this statement is true.
2. Action in the striatum (antiparkinsonian): Bromocriptine is used in the treatment of Parkinson’s disease. It aids in alleviating symptoms by mimicking dopamine, particularly in the brain areas such as the striatum, where dopaminergic pathways are crucial. Hence, this statement is true.
3. Action in CTZ (antiemetic): While dopamine agonists might have activity on chemoreceptor trigger zone (CTZ), bromocriptine does not primarily function as an antiemetic. On the contrary, CTZ stimulation by dopamine can actually induce emesis, making this statement incorrect.
4. Adjunctive treatment for type 2 DM: Bromocriptine has been approved as an adjunct treatment for type 2 diabetes mellitus (DM). It can help improve glycemic control in such patients, making this a true statement.

Based on the analysis:

• Option A: True
• Option B: True
• Option C: False
• Option D: True

The correct set of statements is the combination of A, B, and D only. Therefore, the answer is:

A, B and D only